1. Introduction to Somatic Gene Therapy

Somatic gene therapy is a medical technique in which genetic material is introduced, removed, or modified in the somatic cells (non-reproductive body cells) of a patient to treat or prevent disease

Unlike germline gene therapy, changes made through somatic gene therapy affect only the treated individual and are not inherited by future generations because reproductive cells (sperm and eggs) are not altered.

Examples of diseases targeted by somatic gene therapy include:

• Severe Combined Immunodeficiency (SCID)
• Hemophilia
• Sickle cell disease
• Certain cancers
• Retinal disorders

The regulation of somatic gene therapy attempts to balance:

• Medical innovation
• Patient safety
• Ethical concerns
• Informed consent
• Protection against misuse of genetic technologies

2. Difference Between Somatic and Germline Gene Therapy

3. Regulatory Framework of Somatic Gene Therapy

A. United States Regulation

The United States has one of the most developed regulatory systems for gene therapy.

Major regulatory bodies:

1. Food and Drug Administration (FDA)

The FDA regulates gene therapy products as biological products.

Important regulatory requirements include:

• Preclinical laboratory studies
• Animal testing
• Investigational New Drug (IND) application
• Clinical trials (Phase I, II, III)
• Marketing approval
• Post-market surveillance

The main FDA authority comes from:

• Federal Food, Drug, and Cosmetic Act
• Public Health Service Act

The FDA evaluates:

• Safety of vectors (viral or non-viral carriers)
• Immune reactions
• Long-term risks
• Effectiveness of treatment

B. National Institutes of Health (NIH) Oversight

The NIH historically regulated gene therapy research through the:

Recombinant DNA Advisory Committee (RAC)

The RAC reviewed:

• Ethical issues
• Scientific risks
• Novel gene transfer techniques

Although RAC's role has been reduced, NIH continues oversight of federally funded gene therapy research.

4. European Union Regulation

The European Union regulates gene therapy through:

Advanced Therapy Medicinal Products (ATMP) Regulation

Gene therapy medicinal products are classified as ATMPs.

Regulation involves:

• European Medicines Agency (EMA)
• National competent authorities

Requirements include:

• Quality control
• Clinical safety assessment
• Manufacturing standards
• Long-term monitoring

5. Regulation in India

India regulates somatic gene therapy through multiple authorities.

A. Indian Council of Medical Research (ICMR)

ICMR provides ethical guidelines for biomedical research.

It regulates:

• Human gene therapy research
• Clinical trials
• Ethical approval requirements

B. Department of Biotechnology (DBT)

DBT regulates biotechnology research through:

• Review Committee on Genetic Manipulation (RCGM)
• Institutional Biosafety Committees (IBSC)

C. Central Drugs Standard Control Organization (CDSCO)

CDSCO regulates gene therapy products as drugs.

Requirements include:

• Clinical trial approval
• Safety evaluation
• Manufacturing approval

6. Ethical Issues in Somatic Gene Therapy

1. Informed Consent

Patients must understand:

• Possible benefits
• Unknown risks
• Alternative treatments
• Long-term consequences

2. Safety Risks

Possible risks include:

• Immune reactions
• Insertional mutagenesis
• Cancer development
• Unintended genetic changes

3. Equality and Access

Gene therapy is expensive, raising concerns about:

• Healthcare inequality
• Availability only to wealthy patients

4. Genetic Enhancement

Somatic gene therapy should be used for treatment rather than enhancement of human abilities.

7. Important Case Laws Related to Gene Therapy Regulation

1. Moore v. Regents of the University of California (1990)

Court: Supreme Court of California

Facts:

John Moore underwent treatment for leukemia. Doctors removed his cells and developed a valuable cell line without his permission.

Issue:

Could a patient claim ownership over cells removed from his body?

Decision:

The court held that Moore did not have property rights over his discarded cells but recognized the importance of informed consent.

Importance for Gene Therapy:

This case influenced debates regarding:

• Ownership of genetic material
• Patient consent
• Commercial use of biological materials

Legal principle:
Patients must be informed about possible research and commercial uses of biological materials.

2. Greenberg v. Miami Children's Hospital Research Institute (2003)

Court: United States District Court

Facts:

Families affected by Canavan disease donated genetic materials for research. Researchers later obtained patents relating to the discovery.

Issue:

Could donors claim ownership of genetic discoveries developed from donated samples?

Decision:

The court rejected property claims but recognized concerns regarding informed consent and benefit sharing.

Importance:

The case highlighted:

• Ethical use of genetic samples
• Research transparency
• Rights of genetic donors

3. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Court: U.S. Supreme Court

Facts:

Myriad Genetics obtained patents over BRCA1 and BRCA2 gene sequences.

Issue:

Can naturally occurring human genes be patented?

Decision:

The Supreme Court held that naturally occurring DNA sequences cannot be patented merely because they are isolated.

However, synthetic DNA (cDNA) may qualify for patent protection.

Importance:

The decision affected:

• Genetic research
• Gene therapy development
• Access to genetic information

4. Diamond v. Chakrabarty (1980)

Court: U.S. Supreme Court

Facts:

A genetically engineered bacterium capable of breaking down oil was developed.

Issue:

Can genetically modified organisms be patented?

Decision:

The court allowed patent protection for genetically modified organisms.

Importance:

Although not directly about human gene therapy, it established principles supporting biotechnology innovation.

5. FDA v. Regenerative Sciences, LLC (2014)

Court: United States Court of Appeals

Facts:

A company provided stem-cell-based treatments using manipulated human cells without FDA approval.

Decision:

The court supported FDA authority to regulate biological products.

Importance:

The case confirmed that cell and gene-based therapies require regulatory approval when considered biological products.

8. Famous Gene Therapy Safety Case: Jesse Gelsinger Case (1999)

Although not a traditional court case, it is one of the most important regulatory events.

Facts:

Jesse Gelsinger, an 18-year-old participant in a gene therapy trial for ornithine transcarbamylase deficiency, died after receiving an adenovirus-based gene therapy vector.

Problems Identified:

• Inadequate disclosure of risks
• Conflicts of interest
• Insufficient monitoring

Impact:

The incident resulted in:

• Stricter clinical trial oversight
• Improved informed consent procedures
• Greater FDA monitoring

9. International Regulation

UNESCO Universal Declaration on the Human Genome and Human Rights (1997)

Principles include:

• Respect for human dignity
• Protection of genetic identity
• Prevention of discrimination

Council of Europe Convention on Human Rights and Biomedicine (Oviedo Convention)

It restricts genetic interventions that could affect future generations.

10. Current Regulatory Challenges

1. Long-Term Safety Monitoring

Gene therapy effects may appear years later.

2. Expensive Treatment

Many approved gene therapies cost millions of dollars.

3. Rapid Technological Development

Technologies like CRISPR create new regulatory questions.

4. International Differences

Countries differ in their acceptance and regulation of gene modification.

11. Conclusion

Somatic gene therapy represents a major advancement in modern medicine by allowing treatment of genetic disorders at their biological source. However, because it involves manipulation of human genetic material, strict regulation is necessary.

Regulatory systems worldwide focus on:

• Scientific safety
• Ethical consent
• Patient protection
• Responsible innovation